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Abstract
Background: The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16)
have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2
mutations. Allele frequencies of these polymorphisms were investigated to determine if they
modify risk in BRCA mutation carriers in breast cancer cases drawn from French Canadian cancer
families, a population shown to exhibit strong founder effects.
Methods: The frequencies of the TP53 alleles, genotypes and haplotypes of 157 index breast
cancer cases comprised of 42 BRCA1 mutation carriers, 57 BRCA2 mutation carriers, and 58
BRCA mutation-negative cases, where each case was drawn from independently ascertained
families were compared. The effect of TP53 variants on the age of diagnosis was also investigated
for these groups. The TP53 polymorphisms were also investigated in 112 women of French
Canadian descent with no personal history of cancer.
Results: The BRCA mutation-positive groups had the highest frequency of homozygous carriers
of the 72Pro allele compared with mutation-negative group. The TP53 polymorphisms exhibited
linkage disequilibrium (p < 0.001), where the 72Arg and Ins16minus alleles occurred in strong
disequilibrium. The highest frequency of carriers of Ins16minus-72Arg haplotype occurred in the
BRCA mutation-negative groups. The BRCA1 mutation carriers homozygous for the 72Pro allele
had the youngest ages of diagnosis of breast cancer. However none of these observations were
statistically significant. In contrast, the BRCA2 mutation carriers homozygous for the 72Pro allele
had a significantly older age of diagnosis of breast cancer (p = 0.018). Moreover, in this group, the
mean age of diagnosis of breast cancer in carriers of the Ins16minus-72Arg haplotype was
significantly younger than that of the individuals who did not this carry this haplotype (p = 0.009).
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Conclusion: We observed no significant association of breast cancer risk with TP53 genetic
variants based on BRCA1/2 mutation carrier status. Although the small sample size did not permit
analysis of all possible haplotypes, we observed that BRCA2 mutation carriers harboring the
Ins16minus-72Arg haplotype had a significantly younger mean age of diagnosis of breast cancer.
These observations suggest that investigations in a larger French Canadian sample are warranted
to further elucidate the effects of TP53 variants on age of diagnosis of breast cancer among BRCA1
and BRCA2 mutation carriers.
Background
Approximately 40% of French Canadian breast and/or
ovarian cancer families have been shown to harbor germ-
line mutations in the BRCA1 and BRCA2 cancer suscepti-
bility genes [1-3]. At least five specific mutations in these
genes have been found to recur in cancer families of
French Canadian descent [2-5] and this has been attrib-
uted to common founders [1,3,6-9]. Germline mutations
in BRCA1 and BRCA2 confer a high lifetime risk for breast
and/or ovarian cancer, and early studies of familial cancer
cases suggested that these risks may be as high as 80%
[10,11]. However, lower estimates of lifetime risk for
breast cancer of 66% in BRCA1 carriers and 45% in
BRCA2 carriers were reported in subsequent population-
based studies of pooled data [12,13]. Although various
host factors may influence or modify risk, such as parity
[14], genetic factors have also been proposed as modifiers
of risk, such as genetic variants of HRAS1 [15], the andro-
gen receptor (AR) [16], the 5'UTR of RAD51 [17], and
repeat length polymorphisms in AIB1 [18], not all of
which have been replicated or substantiated in subse-
quent studies [19-21].
Genetic variants of TP53 have received attention as possi-
ble modifiers of cancer risk due to the critical role of p53
in cell cycle control, DNA repair, and apoptosis, and pos-
sible interaction with BRCA1 and BRCA2 [22-24]. Germ-
line mutations in TP53 also confer significantly increased
risk for hereditary breast cancer in the context of the Li
Fraumeni syndrome and Li Fraumeni-like syndrome fam-
ilies, however the overall contribution is less than that
observed for BRCA1 and BRCA2, as was also shown in a
recent study of French Canadian breast and/or ovarian
cancer families [25]. The Arg72Pro (Ex4+199 G>C) and
Ins16 (IVS3+24 ins16) TP53 polymorphisms have been
extensively studied as putative breast cancer susceptibility
variants with inconsistent results [26-42]. These variants
have been shown to affect the in vitro apoptotic activity of
p53 [43-45]. For example, the chemotherapeutic response
was less favorable in ovarian cancer cases retaining the
TP53 72Pro variant which possibly accounts for the over-
all poorer prognosis following treatment of such cases
[46]. A significantly increased familial breast cancer risk
for carriers of the Ins16 variant has also been reported
[42].
Evidence is also emerging that the 72Pro and Ins16 TP53
polymorphisms may modify risk in carriers of BRCA1 or
BRCA2 mutations [45,47]. The 72Pro allele has been
found associated with a younger age of diagnosis of breast
cancer in BRCA1 mutation carriers [47]. In a recent study
of Spanish breast and/or ovarian cancer families, the hap-
lotype lacking the Ins16 allele (referred to as
"Ins16minus") and containing the 72Pro allele was asso-
ciated with a younger age of diagnosis of breast cancer in
BRCA2 mutation carriers than other comparative groups
based on BRCA mutation status [45]. Recently we
reported the frequency of TP53 polymorphisms, includ-
ing 72Pro and Ins16 alleles in a study of the contribution
of germline TP53 mutations in French Canadian breast
and/or ovarian cancer families tested negative for BRCA1
and BRCA2 mutations [25]. However, the frequency of
these polymorphisms and their effect on breast cancer risk
in this founder population was not determined. There-
fore, the aim of the present study was to investigate the
contribution of these polymorphisms in a selected series
of breast cancer cases with known BRCA1 and BRCA2
mutation status that were each drawn from independently
ascertained breast and breast/ovarian cancer families of
French Canadian descent. We report the frequencies of
these alleles in BRCA1 and BRCA2 mutation-positive
cases, and compare these frequencies with mutation-neg-
ative familial breast cancer cases, as well as female French
Canadian controls with no personal history of cancer. The
haplotype frequencies are also reported. In addition, we
investigate the influence of TP53 alleles on the age of diag-
nosis of breast cancer.
Methods
Breast cancer cases and controls
Genotype analyses were performed on 157 breast cancer
cases where each case was drawn from an independently
ascertained cancer family in order to reduce bias due to
familial relationships. Each family had at least three con-
firmed cases of female breast cancer (diagnosed ≤ 65 years
of age), epithelial ovarian cancer, or male breast cancer as
described previously [1-3,25]. The affected individuals in
each family were first-, second- or third-degree relatives
(occurring within the same lineage) to the index case that
was selected for TP53 genotype analysis. Index cases
reported grandparental French Canadian ancestry fromBMC Cancer 2008, 8:96 http://www.biomedcentral.com/1471-2407/8/96
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Quebec, Canada. The index cases from 42 families were
BRCA1 mutation-positive (age range at initial diagnosis of
27 to 65 years; 43.7 years mean age of diagnosis), from 57
families were BRCA2 mutation-positive (age range at ini-
tial diagnosis of 26 to 65 years; 42.7 years mean age of
diagnosis), and 58 cases were mutation-negative (age
range at initial diagnosis of 30 to 65 years; 47.2 years
mean age of diagnosis) based on commercial sequencing
service (Myriad Genetics®, Salt Lake City, UT). Within this
group of index breast cancer cases there were nine breast
cancer cases with primary cancers of the breast and ovary,
of which six individuals were BRCA1 mutation-positive,
two individuals were BRCA2 mutation-positive, and one
case was mutation-negative. The families were ascertained
through the Service de Médecine Génique, Centre Hospi-
talier de l'Université de Montréal (CHUM) and the Hered-
itary Cancer Clinics of McGill University in Montreal. The
controls were comprised of 112 females participants with
no personal history of breast or ovarian cancer ascertained
from the French Canadian population of Quebec.
The clinical samples (pheripheral blood lymphocytes),
and personal and family history were attained from the
study participants at the Centre de recherche du Centre
hospitalier de l'Université de Montréal – Hôpital Hotel-
Dieu and Institut du cancer de Montréal with signed
informed consent as part of the tissue and clinical banking
activities of the Banque de tissus et de données of the Rés-
eau de recherche sur le cancer of the Fonds de la Recherche
en Santé du Québec (FRSQ). The study was granted ethi-
cal approval from the Research Ethics Boards of the partic-
ipating research institutes.
Genotype and haplotype analyses
The Arg72Pro polymorphism refers to the Ex4+199 G>C
variant rs1042522 at nucleotide position 12139, which
results in the nonsynonymous amino acid substitution of
an arginine (72Arg) amino acid at codon 72 with a pro-
line (72Pro) amino acid. The Ins16 polymorphism refers
to the IVS3+24insACCTGGAGGGCTGGGG, the intronic
variant rs17878362 at nucleotide position 11951. For
simplicity genotypes lacking the Ins16 allele are referred
to as "Ins16minus". The nucleotide position is based on
the TP53 reference sequence X54156. The genotyping
assays were performed on DNA extracted from peripheral
blood leukoctyes. The Arg72Pro and Ins16 polymor-
phisms were assayed as described previously [25]. Haplo-
types were determined as described in Osorio A. et al.,
2006 [45].
Statistical analyses
Allele, genotype and haplotype frequency distributions
were compared by Monte-Carlo χ2 analyses (Statistical
Product and Service Solution Package, SPSS, Chicago, IL).
Hardy-Weinberg equilibrium (HWE) for each polymor-
phism was tested by Monte-Carlo Markov Chain [48].
Linkage disequilibrium analysis and D' estimation were
performed using the Arlequin v2.0 software package. A
one-way ANOVA test was used to compare age related
effects (onset of breast cancer). Kruskal-Wallis test was
used where appropriate.
Results
Allele and Genotype frequencies in cases and controls
The genotype and allele frequencies of the TP53 polymor-
phisms from 112 controls and 157 index breast cancer
cases each selected from an independently ascertained
cancer family was determined. The controls had more
individuals that were homozygous for the 72Pro allele
than that of the cases, and this was also reflected in a
higher 72Pro allele frequency (Table 1). In contrast, the
cases had more individuals that were homozygous for the
Ins16 allele than that the controls (Table 2). These find-
ings are also reflected in the allele frequencies for these
polymorphisms. However, the differences in genotype fre-
quencies are not significant (Tables 1 and 2).
Haplotype analysis revealed that the TP53 polymor-
phisms are in linkage disequilibrium (D' = 0.80 – 0.93, for
all test groups, p < 0.001), where the 72Arg and
Ins16minus alleles occurred in strong disequilibrium. All
possible double haplotypes were observed in the cases
(Table 3), whereas there were no examples of Ins16-
72Arg, Ins16-72Pro or Ins16-72Arg, Ins16minus-72Pro
Table 1: Frequency of Ex4+199 G>C (72Pro) allele
Genotypic frequencies (%) P values Allele frequencies (%) HWE
Group Sampl 
number e
GG 
(Arg, Arg)
GC 
(Arg, Pro)
CC 
(Pro, Pro)
All cases BRCA2+ BRCA- G C P value
Controls 112 57 (50.9) 46 (41.1) 9 (8.0) 0.84 160 (71.4) 64 (28.6) 1
All cases 157 80 (51.0) 67 (42.7) 10 (6.3) 227 (72.3) 87 (27.7) 0.55
BRCA1+ 42 20 (47.6) 18 (42.9) 4 (9.5) 0.86 0.47 58 (69.0) 26 (31.0) 1
BRCA2+ 57 29 (50.9) 24 (42.1) 4 (7.0) 0.78 82 (71.9) 32 (28.1) 1
BRCA- 58 31 (53.4) 25 (43.1) 2 (3.4) 87 (75.0) 29 (25.0) 0.47
BRCA1/2+ 99 49 (49.5) 42 (42.5) 8 (8.0) 0.57 140 (70.7) 58 (29.3) 1BMC Cancer 2008, 8:96 http://www.biomedcentral.com/1471-2407/8/96
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double haplotypes in the controls. However, there was
only one example of each of these double haplotypes in
the cases. Moreover, the distribution of the double haplo-
types in the cases did not differ significantly from that of
the controls. The paucity of some double haplotypes did
not permit an analysis of all possible double haplotypes.
However, notable is that the distribution of the
Ins16minus-72Arg double haplotype in the cases (145 of
157, 92.4%) and controls (103 of 112, 91.7%) were sim-
ilar (OR = 1.06 (95% CI 0.44 – 2.54), p = 1.
Genotype and Allele Frequencies of Hereditary and 
Familial Cases of Breast Cancer
The genotype frequencies of the TP53 polymorphisms in
each of the three breast cancer cases groups based on
BRCA mutation status were determined. Each of the
BRCA1 and BRCA2 mutation-positive groups had the
highest frequency of homozygous carriers of the 72Pro
allele when compared with that of the mutation-negative
group (Table 1). Homozygous carriers of the Ins16 allele
were only observed in BRCA2 mutation-positive carriers
(Table 2). However, neither of these differences nor the
distribution of all genotypes were significantly different in
all pair-wise comparisons of the three groups, or when the
BRCA mutation-positive groups were combined in the
analyses for each polymorphism.
The distribution of all possible double haplotypes in the
cases is shown in Table 3. None of the breast cancer case
groups had individuals with all possible double haployt-
pes. The highest frequency of carriers of the Ins16minus-
72Arg haplotype, which is in strong disequilibrium, was
within the mutation-negative group. The BRCA mutation-
negative group had the highest frequency of carriers of the
Ins16minus-72Arg haplotype (56 of 58, 96.6%). How-
ever, this observation was not significantly different from
that observed in either of the BRCA1 mutation-positive
(38 of 42, 90.5%) and BRCA2 mutation-positive (51 of
57, 89.5%) groups (p = 0.29).
Age effects
Overall, the BRCA mutation-negative cases had a signifi-
cantly older mean age of diagnosis of breast cancer than
each of the BRCA1 and BRCA2 mutation-positive groups
(p = 0.02), as has been observed in previous studies of
French Canadian breast cancer families [2]. The differ-
ences in age of diagnosis of breast cancer in the BRCA1
and BRCA2 mutation-positive groups did not permit the
combined analysis of these groups versus mutation-nega-
tive group. We therefore investigated the ages of diagnoses
of breast cancer within each group separately with respect
to each TP53 polymorphism (Figure 1). Within the
BRCA1 mutation-positive group, homozygous 72Pro car-
riers had the youngest ages of diagnoses of breast cancer
than that of the homozygous 72Arg (p = 0.31) and heter-
Table 3: Frequency of double haplotypes
Double haplotype frequencies (%) P value
Group Sample 
number
-G -G -G +G -G -C -G +C +G -C +G +C -C -C -C +C +C +C All 
cases
BRCA2
+
BRCA-
Control
s
112 55 (49.1) 2 (1.8) 21 (18.8) 25 (22.3) 0 0 2 (1.8) 6 (5.4) 1 (1.0) 0.98
All 
cases
157 74 (47.1) 5 (3.2) 26 (16.6) 40 (25.5) 1 (0.6) 1 (0.6) 2 (1.2) 7 (4.5) 1 (0.6)
BRCA1
+
42 18 (42.9) 2 (4.8) 7 (16.7) 11 (26.2) 0 0 1 (2.4) 3 (7.1) 0 0.94 0.61
BRCA2
+
57 26 (45.6) 2 (3.5) 12 (21.1) 11 (19.3) 1 (1.8) 1 (1.8) 0 3 (5.3) 1 (1.8) 0.34
BRCA- 58 30 (51.7) 1 (1.7) 7 (12.1) 18 (31.0) 0 0 1 (1.7) 1 (1.7) 0
BRCA1/
2+
99 44 (44.4) 4 (4.0) 19 (19.2) 22 (22.2) 1 (1.0) 1 (1.0) 1 (1.0) 6 (6.1) 1 (1.0) 0.61
Table 2: Frequency of IVS3+24 ins16 (+) allele
Genotypic frequencies (%) P values Allele frequencies (%) HWE
Group Sample number - - - + + + All cases BRCA2+ BRCA- - + P value
Controls 112 79 (70.5) 32 (28.6) 1 (0.9) 0.65 190 (84.8) 34 (15.2) 0.46
All cases 157 102 (65.0) 53 (33.8) 2 (1.2) 257 (81.8) 57 (18.2) 0.11
BRCA1+ 42 26 (61.9) 16 (38.1) 0 0.48 0.83 68 (81.0) 16 (19.0) 0.31
BRCA2+ 57 38 (66.7) 17 (29.8) 2 (3.5) 0.46 93 (81.6) 21 (18.4) 1
BRCA- 58 38 (65.5) 20 (34.5) 0 96 (82.8) 20 (17.2) 0.19
BRCA1/2+ 99 64 (64.7) 33 (33.3) 2 (2.0) 0.76 161 (81.3) 37 (18.7) 0.18BMC Cancer 2008, 8:96 http://www.biomedcentral.com/1471-2407/8/96
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ozygous (p = 0.36) carriers, although these observations
were not significant. Within the BRCA2 mutation-positive
group, homozygous 72Pro carriers had a significantly
older age of diagnosis of breast cancer compared to the
mean age of diagnosis of either of the homozygous 72Arg
(p = 0.041) and heterozygous (p = 0.018) carriers. Within
the BRCA2 mutation-positive group, homozygous Ins16
carriers had a significantly older age of diagnosis of breast
cancer compared to the mean age of diagnosis of either of
the homozygous Ins16minus (p = 0.042) or heterozygous
(p = 0.046) carriers.
The low frequency of all double haplotypes did not per-
mit an investigation of each possible combination with
respect to age of diagnosis of breast cancer (Figure 2).
However, we were able to analyze the combined data for
carriers of the Ins16minus and 72Arg alleles as these alle-
les were in strong linkage disequilibrium. Within the
BRCA2 mutation-positive group, carriers of the
Ins16minus-72Arg haplotype had a significantly younger
mean age of diagnosis of breast cancer (p = 0.009). Indeed
the mean age of diagnosis of breast cancer at 41.7 years of
the 51 Ins16minus-72Arg carriers was significantly
younger than that of the six cases that did not carry this
haplotype.
Discussion
While there was an increased frequency of homozygous
carriers of 72Pro alleles in BRCA1 and BRCA2 mutation
carriers, and an increased frequency of homozygous carri-
ers of Ins16 alleles in BRCA2 mutation carriers in familial
breast cancer cases of French Canadian descent, the find-
ings were not significant. The distribution of genotype fre-
quencies was not significantly different in the controls or
cancer cases in this study. Moreover, the distribution of
genotypes and alleles of the unaffected controls and cases
were comparable and not significantly different than that
of European (or Caucasian) population as reported in the
Single Nucleotide Polymorphism Database [49], a popu-
lation that is historically or ancestrally linked with the
French Canadians of Quebec [7]. These results suggest
that there are no significant differences in the genotype
frequencies in breast cancer cases regardless of the BRCA1
or BRCA2 mutation status. In independent reports of
TP53 allele frequencies in cancer cases of BRCA1/2-muta-
tion carriers, the relationships among carriers is not
always apparent. In our study, in order to reduce bias due
to the possibility of close familial relationships, we have
purposely drawn our cases from independently ascer-
tained families where (to our knowledge) the family
members are not known to be directly related to each
other [1-3]. However, our study size may be limited and
further analysis of larger sample groups is warranted given
the apparent increased frequency of homozygous carriers
of rare alleles for both genotypes in BRCA1/2 mutation
carriers when compared with mutation-negative cases.
Although there were differences in the ages of diagnosis of
breast cancer in homozygous carriers of the 72Pro allele in
BRCA1 and BRCA2 mutation positive groups, the mean
age of diagnoses were not significantly different. BRCA2
mutation carriers homozygous for the 72Pro allele had an
older mean age of diagnosis of breast cancer compared
with breast cancer cases homozygous for the 72Arg allele
and heterozygous carriers of this TP53 polymorphism, but
overall the difference was not statistically significant.
Although our studies were limited in size and are not sig-
nificant, the younger mean age of diagnosis of breast can-
cer in BRCA1 mutation carriers homozygous for the 72Pro
allele is consistent with independent reports suggesting
that this allele may modify penetrance of BRCA1 carriers
[47]. The independent report of the effect on age of diag-
nosis of breast cancer of the Ins16minus-72Pro haplotype
in BRCA2 mutation carriers [45] was not observed in our
study. However, we observed that among the BRCA2
mutation-positive cases, carriers of the Ins16minus-72Arg
haplotype had a significantly younger mean age of diag-
nosis of breast cancer compared to the other individuals
within this group. However, haplotype analysis suggested
that the two polymorphic loci were in strong linkage dis-
equilibrium in our samples. Although the extent of the
linkage disequilibrium for the TP53 has not been properly
investigated in this population, haplotype analysis of
BRCA1 and BRCA2 loci of carriers of recurrent mutations
have shown it could extend beyond at least one centri-
Morgan [1,3,6]. This observation was not surprising given
the strong founder effects observed in the French Cana-
dian population and the fact that the present day popula-
tion are descendents of an estimated 8,500 settlers who
colonized the present day St. Lawrence valley ("Nouvelle
France") in recent history between 1608 and 1759 [7,8].
Hence, the young age of this founder population may also
explain the relative paucity of individuals with the Ins16-
72Arg haplotype in our sample groups.
Conclusion
The analysis of TP53 alleles, 72Pro and Ins16, in French
Canadians suggest that they do not significantly modify
familial breast cancer risk. However our analyses may be
affected by sample size and strong linkage disequilibrium
observed in this population for the tested alleles. While
additional breast cancer cases drawn from within each
cancer families could have been included in our analyses
as has been done in previous studies [25], this may further
bias results due to the founder effects and linkage disequi-
librium observed for the tested alleles in this population.
However, the difference in homozygous allele frequencies
of rare genotypes in this population warrants further
investigation with a larger sample.BMC Cancer 2008, 8:96 http://www.biomedcentral.com/1471-2407/8/96
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Scatter plots of the age at diagnoses of breast cancer based on BRCA mutation status and genotypes of each TP53 polymor- phism Figure 1
Scatter plots of the age at diagnoses of breast cancer based on BRCA mutation status and genotypes of each TP53 polymorphism. 
Panel A contains the age distribution of Arg72pro polymorphism based on BRCA mutation status for homozygous carriers of 72Arg (GG) and 72Pro (CC) 
genotypes or heterozygous carriers (GC). For the BRCA1 mutation-positive group, the G,G carriers (n = 20) had a mean age ± st. err.(standard error) = 
43.9 ± 2.1; the GC carriers (n = 18) had mean age ± st. err. = 44.4 ± 2.3; and the CC carriers (n = 4) had a mean age ± st. err. = 39.5 ± 6.6. For the 
BRCA2 mutation-positive group, the GG carriers (n = 29) had a mean age ± st. err = 43 ± 1.6; the GC carriers (n = 24) had a mean age ± st. err. = 40.5 ± 
1.7; and the CC carrier (n = 4) had a mean age ± st. err. = 53 ± 4.8. For the BRCA mutation-negative group, the GG carriers (n = 31) had a mean age ± st. 
err. = 48.1 ± 1.5; the GC carriers (n = 25) had a mean age ± st. err. = 46.0 ± 1.5; and the CC carriers (n = 2) had a mean age ± st. err. = 48 ± 11. Panel B 
contains the age distribution of Ins16 polymorphism based on BRCA mutation status for homozygous carriers Ins16minus [- -] and ins16 [+ +] genotypes 
or heterozygous carriers [- +]. For the BRCA1 mutation-positive group, the [- -] carriers (n = 26) had a mean age ± st. err. = 41.7 ± 1.9; the [- +] carriers 
(n = 16) had a mean age ± st. err. = 46.9 ± 2.3; and there were no homozygous [+ +] carriers. For the BRCA2 mutation-positive group, the [- -] carriers 
(n = 38) had a mean age ± st. err. = 43 ± 1.4; the [- +] carriers (n = 17) had a mean age ± st. err. = 40.5 ± 2.0; and the [+ +] carriers (n = 2) had a mean 
age ± st. err. = 55 ± 1. For the BRCA mutation-negative group, the [- -] carriers (n = 38) had a mean age ± st. err. = 47.3 ± 1.5; the [- +] carriers (n = 20) 
had a mean age ± st. err. = 46.9 ± 1.5; and there were no homozygous [+ +] carriers.
A
GG              GC                 CC      GG              GC    CC      GG               GC               CC
BRCA1                                  BRCA2                     BRCA-
B
[– –] [– +] [– –] [– +] [+ +]   [– –] [– +]
BRCA1                                   BRCA2                    BRCA-BMC Cancer 2008, 8:96 http://www.biomedcentral.com/1471-2407/8/96
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